� How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape , with no targeted therapy currently available to address this patient subset ?
� The market forecasts indicate that Japan will contribute the most to the Asia- Pacific market value due to the emergence of novel therapies .
� How will the annual cost of therapy and market size vary between the five Asia-Pacific markets ?
� How could changes in risk factors such as population age , smoking habits and pollution influence the market ?
� Licensing deals are the most common form of strategic alliance in NSCLC , with total deal values ranging from under $ 10m to over $ 1 billion .
� How do deal frequency and value compare between target families and molecule types ?
� What were the terms and conditions of key licensing deals ?
Reasons to buy This report will allow you to -
� Understand the current clinical and commercial landscape by considering disease pathogenesis , diagnosis , prognosis , and the treatment options available at each stage of diagnosis , including a clinical comparison of marketed therapies .
� Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing . Unmet needs are highlighted to allow a competitive understanding of gaps in the current market .
� Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development , molecule type and molecular target .
� Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period , highlighting clinical performance , potential commercial positioning , and how they will compete with other therapies .
� Predict NSCLC market growth in the five Asia-Pacific markets , with epidemiological and annual cost of therapy forecasts across India , China , Australia , South Korea and Japan , as well as the individual contributions of promising late-stage molecules to market growth .